Compare ARDX & ADTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | ADTN |
|---|---|---|
| Founded | 2007 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2014 | 1996 |
| Metric | ARDX | ADTN |
|---|---|---|
| Price | $6.97 | $14.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $15.14 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 3.8M | 2.8M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 90.83 |
| EPS | N/A | ★ N/A |
| Revenue | $2,607,000.00 | ★ $1,083,807,000.00 |
| Revenue This Year | $37.75 | $11.09 |
| Revenue Next Year | $34.24 | $8.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.46 |
| 52 Week Low | $3.54 | $7.11 |
| 52 Week High | $8.40 | $18.69 |
| Indicator | ARDX | ADTN |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 43.81 |
| Support Level | $6.83 | $8.39 |
| Resistance Level | $8.23 | $17.99 |
| Average True Range (ATR) | 0.36 | 0.90 |
| MACD | 0.11 | -0.42 |
| Stochastic Oscillator | 69.88 | 4.30 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.